Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by NiKang Therapeutics Inc.

NiKang Therapeutics® Presents Discovery of NKT3964, a First-in-Class, Highly Potent and Selective, Orally Bioavailable CDK2 PROTAC Degrader for Cancer Therapy, at the EORTC-NCI-AACR Symposium 2024
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics Appoints Joanne Lager, M.D., as Chief Medical Officer
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics Enters into Clinical Trial Collaboration and Supply Agreement to Evaluate NKT2152 in Combination with Standard-of-Care in First-Line Advanced Hepatocellular Carcinoma
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics Appoints Anne E. Borgman, M.D., to Board of Directors
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics Presents Preclinical Data Highlighting NKT2152’s Therapeutic Potential in Clear Cell Renal Cell Carcinoma (ccRCC) and Solid Tumors Beyond ccRCC at AACR Annual Meeting 2022
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
From NiKang Therapeutics Inc.
Via Business Wire
Tickers AVEO
NiKang Therapeutics and Pfizer Enter Clinical Trial Collaboration and Supply Agreement to Evaluate Novel Combination Therapies for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics Announces First Patient Dosed in A Phase 1/2 Study Evaluating NKT2152, a Small Molecule that Inhibits Hypoxia Inducible Factor 2α (HIF2α), for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics Appoints Robert Xin, M.D., Ph.D., as Chief Medical Officer
From NiKang Therapeutics Inc.
Via Business Wire
NiKang Therapeutics Announces Completion of $200 Million Series C Financing to Advance Highly Differentiated Small Molecules Addressing Difficult-to-Drug Targets
From NiKang Therapeutics Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.